Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 44.4% in March

Aditxt, Inc. (NASDAQ:ADTX) was the target of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 19,500 shares, a decline of 44.4% from the March 15th total of 35,100 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average daily trading volume, of 391,600 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Aditxt during the second quarter valued at $71,000. Bank of New York Mellon Corp acquired a new position in Aditxt during the third quarter valued at $119,000. Schonfeld Strategic Advisors LLC acquired a new position in Aditxt during the third quarter valued at $423,000. Finally, Armistice Capital LLC acquired a new position in Aditxt during the third quarter valued at $350,000. 15.54% of the stock is currently owned by institutional investors and hedge funds.

Aditxt Trading Down 5.5 %

NASDAQ:ADTX opened at $3.12 on Thursday. Aditxt has a 12 month low of $2.95 and a 12 month high of $76.40. The firm has a fifty day simple moving average of $3.50 and a 200-day simple moving average of $5.31.

About Aditxt

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.